Latest Conference Articles

Thomas Sherrer, PharmD, advocates for a team-driven, tech-enhanced approach to pharmacy inventory management, boosting patient care and operational efficiency.

Brooklyn Morgan, PharmD, director of state policy at the National Alliance of State Pharmacy Associations, emphasizes the importance of making the pharmacist's voice heard.

Congressman Buddy Carter (R-GA) champions the PBM Reform Act of 2025, aiming to enhance drug price transparency and empower pharmacists in healthcare delivery.

Pharmacists left the conference with fresh ideas, renewed confidence, and a strong sense that they're not in this alone.

Thomas Sherrer, PharmD, co-owner of Poole's Pharmacy, describes implementing multiple tracking methods to stay ahead of drug shortages.

Crystal Lennartz, president of Health Mart & Health Mart Atlas at McKesson, discusses challenges that independent pharmacies are facing in today's health care landscape.

Jeanine Singer, senior vice president of national and key accounts at McKesson, discusses the company's approach to empowering pharmacists and strengthening the community pharmacy ecosystem.

Through platforms like Health Mart Atlas, the company is providing pharmacies with tools to better understand their financial landscape.

Thomas Sherrer, PharmD, emphasizes the importance of a team-based approach to inventory control.

Pharmacists can transform from only being prescription dispensers to health care hubs that offer comprehensive patient care and generate innovative revenue streams.

The key theme, regardless of strategy, is being an engaging member of the community and stepping outside of the counter.

This year’s conference is taking place from July 10 to 13 in Nashville, Tennessee.

Following his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter caught up with Drug Topics to discuss the pharmacists’ role in diabetes management.

Researchers explored patients with type 1 diabetes and overweight or obesity to understand the efficacy and safety of GLP-1s as adjunctive therapies.

In a recap of his presentation at the American Diabetes Association’s 85th Scientific Sessions, Jon Easter, RPh, discussed the role of pharmacists in team-based diabetes care.

In an abstract presented at the American Diabetes Association 85th Scientific Sessions, researchers tested the effectiveness of an AI-driven program for improving glycemic control.

Jon Easter, RPh, discusses pharmacists’ ability to improve patient engagement in diabetes care following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

Jon Easter, RPh, joined Drug Topics to discuss pharmacists’ roles within health care teams following his presentation at the American Diabetes Association’s 85th Scientific Sessions.

Clinical pharmacists transform diabetes care by leveraging manufacturer-sponsored patient assistance programs to dramatically improve medication access.

An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.

Results from the CATALYST trial showed patients who received mifepristone had a mean HbA1c reduction of 1.47%,

Nathan Ramsbacher, PharmD, emphasizes that one of the most significant barriers to clinical quality is patients' inability to access crucial medications due to cost.

From 2019 to 2024, GLP-1 prescriptions among pediatric patients with type 2 diabetes increased from 12.3% to 60.9%.

The most frequent barriers to access to glucagon include cost, patient health literacy, and insurance coverage.

Researchers explored the prevalence of obesity-related complications and obesity medication use in US children and young adults with obesity.

The initiative focuses on managing medications for high-risk diabetes patients through a collaborative drug therapy agreement.

Researchers presented an abstract describing current racial disparities in CGM access and wear time to better inform quality improvement efforts.

Researchers explored the impact of a $0 copay program on hemoglobin A1c levels in patients with type 2 diabetes who were also insured by Blue Cross and Blue Shield of Louisiana.